Recovery

TB-500

Thymosin β-4 fragment with documented actin-binding and pro-angiogenic activity. Stacks with BPC-157 for tendon, ligament, and soft-tissue recovery. Animal model evidence robust; no human RCT. Interim FDA Category 2 status pending the July 2026 PCAC meeting.

Medically reviewed by Marko Maal · May 10, 2026

Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 10, 2026

Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.

What the community reports — TB-500

distilled from 8 Reddit posts

Users report TB-500 for injury recovery via local injection; some note abdominal/GI effects.

Reported dose: 500 mcg daily; 750 mcg daily
Route: subcutaneous injection
Frequency: daily; bi-weekly
Side effects: lower abdominal tightness/pressure, constipation, reduced gut motility, injection site pain
Often stacked with: BPC-157, GHK-CU, Retatrutide

Ask about TB-500

Get an answer from our reviewed articles and community reports, with links to the sources. Not medical advice.

Mechanism

Evidence tier: 3 — Mechanism characterized in foundational Goldstein 2005 + Malinda 1999 animal-RCT and in-vitro work; human clinical mechanism data is thinner.

TB-500 is a synthetic 17-amino-acid fragment of thymosin β-4 (Tβ4), the dominant G-actin-sequestering peptide in mammalian cells. The fragment includes the active LKKTETQ binding domain that mediates Tβ4's actin interactions. Mechanistically, TB-500 functions upstream of cytoskeletal reorganization — it binds monomeric G-actin and modulates F-actin polymerization, which in turn supports cell migration, angiogenesis, and tissue remodeling. Goldstein 2005 (PMID 16099219) characterized the actin-sequestering biology and the broader "moonlighting" role of Tβ4 in tissue repair. The downstream effects relevant to community use cases — endothelial cell migration into wound beds, fibroblast recruitment, and modulation of inflammatory cytokine signaling — were demonstrated in the Malinda 1999 wound-healing animal work (PMID 10469335) and subsequent cardiac and corneal injury models. TB-500's effect profile is distinct from but complementary to BPC-157's VEGF-driven angiogenic signaling, which is why the two are commonly stacked.

Typical protocols

Evidence tier: 5 — Community-evolved dosing; no completed human RCT has validated the schedule. Documenting what's in use, not endorsing it.

Community protocols typically use a two-phase schedule. Loading phase (weeks 1-4 to 1-6): 2.0-2.5 mg subcutaneously twice weekly, totaling 4-5 mg per week. Maintenance phase (weeks 4-12 or 6-12): 2.0-2.5 mg subcutaneously once weekly. Total cycle length is most commonly 8-12 weeks. Injection is subcutaneous; site rotation between abdomen and thigh is standard. Some protocols site-inject near the indication (e.g., abdominal subcutaneous tissue for systemic effect, periarticular for joint indications) — the evidence base does not clearly support one approach over the other in humans. The dominant use case in 2026 is the BPC-157 + TB-500 stack for post-surgical or tendinopathy recovery — see the full recovery stack walkthrough. Dosing in trial-grade Tβ4 work (RGN-259 corneal eye drops, RGN-352 cardiac IV) used different routes and concentrations and is not directly translatable to subcutaneous community protocols.

Evidence by indication

Evidence tier: 3 — Tendon, cardiac, and corneal models have animal-RCT evidence; human translation is small Phase 1/2 data in adjacent formulations.

Tendon and soft-tissue repair (animal): Multiple rat and rabbit models of Achilles tendon transection and ligament injury show accelerated repair with Tβ4 administration. Cellular-migration and angiogenic mechanisms are consistently demonstrated.

Wound healing (animal + Phase 2 human, related compound): Malinda 1999 (PMID 10469335) established accelerated dermal wound healing in rodents. The full-length Tβ4 product (RGN-137) progressed to Phase 2 in epidermolysis bullosa with mixed signal.

Cardiac repair (animal): Bock-Marquette 2004 demonstrated Tβ4 cardioprotection in murine MI models. RGN-352 (IV Tβ4) entered early human trials in cardiac indications; the program was discontinued for non-efficacy reasons.

Corneal wound healing (Phase 2/3 human, related compound): RGN-259 topical Tβ4 eye drops reached Phase 3 for dry eye and neurotrophic keratitis with mixed primary-endpoint outcomes.

Combination with BPC-157 in soft-tissue recovery: Tier 5 — no RCT data on the combination as a unified protocol. The mechanistic rationale (BPC-157 vascular signaling + TB-500 cytoskeletal/migration) is plausible. The empirical evidence is community-anecdotal.

Cross-link: see the BPC-157 vs TB-500 comparison and the peptides for tendinopathy article for indication-specific positioning.

Safety profile

Evidence tier: 3 — Animal toxicology and limited human Phase 1/2 data with related Tβ4 compounds; long-term human safety data is absent.

TB-500 has a clean profile in animal toxicology studies at therapeutic doses. The most consistent human reports from community use are mild and transient: injection-site erythema, low-grade fatigue or "head fog" in the first 24-72 hours of loading, occasional dizziness. No serious adverse-event signal has emerged in published case series.

The mechanistic concerns that remain theoretical: angiogenesis promotion is a relative contraindication in patients with active or recent malignancy, particularly tumor types where neovascularization drives progression. The actin-sequestering mechanism is broadly distributed across tissue types and the long-term effect on tissues with high mitotic activity is not characterized in chronic human dosing. Patients with active autoimmune disease should discuss with a clinician — the inflammatory modulation is bidirectional. WADA prohibits TB-500 in-competition and out-of-competition; athletes subject to testing should not use it.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning combining mechanism + evidence tier; the closest direct comparator is BPC-157.

The most direct comparator is BPC-157, which has stronger preclinical tendon-healing data and similar animal-RCT evidence quality. TB-500 is preferred over BPC-157 monotherapy when cardiac or broader systemic repair is part of the indication, when the patient has failed a BPC-157-only trial, or when the community-evolved combination protocol is being used. For dermal wound healing, GHK-Cu has more direct human data than TB-500 — see the recovery stack for how the three molecules are typically combined. For tendinopathy specifically, BPC-157 is usually first-line in community practice with TB-500 added in non-responders or surgical-recovery contexts. There is no scenario where TB-500 displaces validated standard-of-care interventions (physical therapy, PRP for selected indications, surgical revision when indicated) — it sits as adjunct, not replacement.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

TB-500 currently sits at Interim FDA Category 2 status pending the PCAC July 23, 2026 meeting that will formally evaluate it for the 503A bulks list. Many 503A compounding pharmacies stopped dispensing during 2024-2025 enforcement actions; a smaller number continue under contested legal theories with documented medical necessity. Telehealth providers with 503A partnerships remain a primary patient-access pathway — see our clinic directory filtered for recovery indications. Research-supplier sourcing is strongly discouraged due to purity and contamination risk plus the regulatory exposure to the patient. WADA-prohibited; athletes should not use it. The July 2026 PCAC decision is the key regulatory inflection point for 2026.

References

Goldstein AL, Hannappel E, Kleinman HK. 2005. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. PMID 16099219
Malinda KM, Sidhu GS, Mani H, et al. 1999. Thymosin β4 accelerates wound healing. J Invest Dermatol. PMID 10469335
Sikiric P, Seiwerth S, Brcic L, et al. 2010. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Curr Pharm Des. PMID 20388964
FDA. Pharmacy Compounding Advisory Committee — July 2026 meeting agenda. fda.gov

Limitations

TB-500 should not be used in patients with active or recent malignancy (the angiogenic mechanism is a relative contraindication, particularly for tumor types where neovascularization drives progression), patients on therapeutic anticoagulation without surgical-team review, pregnant or nursing patients, anyone subject to WADA testing, or pediatric patients. Self-sourced research-supplier material is unsuitable for any patient given purity and contamination risk.

The cited evidence cannot tell us whether subcutaneous TB-500 dosing produces effects comparable to the IV Tβ4 used in Phase 1/2 cardiac and corneal trials, what the optimal dose-response relationship is in human soft-tissue repair, or whether the BPC-157 + TB-500 combination outperforms BPC-157 monotherapy in a controlled trial. We would change our framing on the July 2026 PCAC decision, publication of any human RCT of TB-500 in a tendinopathy or post-surgical indication, or completion of a stack-vs-monotherapy comparison.

External · Independent testing

Verify what's actually in your TB-500 vial

Gray-market peptide vials vary widely on identity, purity, and labeled concentration. Finnrick is an independent testing platform that ships consumer-submitted samples to commercial labs and publishes every result in a free public database. Vendors cannot pay for placement or to suppress a result. We don't operate Finnrick — we link to it because post-purchase verification is the right complement to pre-purchase clinical evidence.

See TB-500 vendor results on Finnrick r/saferpeptides community ↗

Finnrick is independent; we receive no compensation for this link. US-resident free testing as of May 2026.

Where to buy

TB-500 — cheapest verified vendors

Vendor	Product	Size	Price	Price / mg	Trust
Reta Peptide	TB-500 100mg	100 mg vial	$120.00	$1.20/mg	40	Buy
EZ Peptides	TB-500 10mg	10 mg vial	$48.00	$4.80/mg	40	Buy
Skye Peptides	TB-500 25mg	25 mg vial	$129.00	$5.16/mg	40	Price n/a
Peptidology	TB-500 10mg	10 mg vial	$56.99	$5.70/mg	40	Price n/a
Atomik Labz	TB-500 100mg	100 mg vial	$585.00	$5.85/mg	40	Price n/a

Prices refreshed 1 day ago. Links may be affiliate links; how are trust scores calculated?

See all 55 vendors for TB-500 →

What Reddit users report — TB-500

Best-rated real posts mentioning TB-500, summarized with a short quote in the poster’s own words. Of these: 1 worked · 3 mixed · 1 didn't work. Anecdotal community signal — not evidence, not medical advice, and not endorsement.

~ Mixedr/Peptides
User reported lower left abdominal tightness and pressure for one month while taking GHK-CU, BPC-157/TB-500, and Retatrutide together. Uncertain of cause; planning medical evaluation.
“Around a month ago, I started getting this weird feeling in the lower left side of my abdomen.”
— u/Sea_Wealth1266 · read on Reddit ↗
~ Mixedr/bpc_157
Poster used TB-500 bi-weekly alongside BPC-157 before developing appendicitis. Now considering resuming peptides for shoulder injury despite potential gut motility concerns.
“In some rare cases people talk about it slowing gut motility which increases constipation which can in turn cause appendicitis.”
— u/RecordingMountain585 · read on Reddit ↗
✓ Workedr/Peptides
User reports reduced swelling and increased knee mobility after ~1 month of daily TB-500 and BPC-157 injections near femur fracture surgical site.
“Within about a week or two, I was able to bend my knee significantly more.”
— u/Tajinder356 · read on Reddit ↗
✗ Didn't workr/Peptides
Poster seeks testing methods for TB-500 and BPC-157 peptides to help friend recover from surgery, but has not personally used these peptides.
“Had I had the funds 2 years ago after my MRSA infection surgery I would have attempted to take these to promote healing”
— u/Mit_Raptor · read on Reddit ↗
~ Mixedr/Peptides
User asks whether adding BPC-157/TB-500 stack would be excessive while already using 2mg daily of another peptide for shoulder issues.
“I've been having some shoulder issues and was wondering if it would be over kill to add Bpc-157/tb-500 stack??”
— u/lonesome68 · read on Reddit ↗

Posts are pulled from public Reddit threads and summarized for context. Individual experiences vary widely and don’t predict your own results. Always consult a qualified clinician.

Community signal — TB-500

Recent posts and videos mentioning TB-500 from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

Community experiences

1 approved · moderated

First-hand accounts from readers who've used TB-500. These are personal anecdotes, not clinical evidence or medical advice — every post is reviewed before it appears.

Marcus T·17d ago·4 min read
Member
TB-500 + BPC-157 experience — Marcus T
I’m a former college volleyball player, and I got into CrossFit at 38. By 41, I had reached that very humbling stage of “this used to be fine, so why does everything hurt now?” Both shoulders were irritated, mostly impingement-type symptoms, and my right Achilles had become a long-running problem.
Physical therapy helped, to be fair. It got me functional again, but not really back to where I wanted to be. I’d say I was maybe 60% there. I could train, but I was constantly modifying things, avoiding certain movements, and making deals with my body every time I walked into the gym.
I tried PRP for the shoulder first. It helped for maybe four months, and then the pain slowly started creeping back in. I also looked into stem cells, but the consult came back at $8,400, which was an immediate no. I first heard about BPC-157 on a podcast, then again from a training partner who had been around the TRT and peptide world for a while. I was skeptical, but I was also tired of guessing.
I started with oral BPC-157 arginate at 500 mcg twice a day for eight weeks. I didn’t stack it with anything else at the beginning, and I didn’t build a formal rehab plan around it, which I now think was a mistake. The first two weeks were basically uneventful. I wanted to feel something, but I didn’t. The only thing I noticed was mild nausea if I took the oral BPC on an empty stomach.
Around weeks three and four, my Achilles morning stiffness started to improve. It wasn’t fixed, but getting out of bed and walking downstairs didn’t feel as sketchy. That was the first small sign that maybe something was happening. My shoulder, however, felt exactly the same.
By weeks five to eight, the Achilles improvement was more noticeable. I was able to jump rope without pain for the first time in about 18 months. Not a huge amount, and not aggressively, but enough that I noticed. That said, I still wouldn’t call the oral BPC dramatic. Maybe it helped a little. Maybe it was time, consistency, or a combination of things. The shoulder still had that annoying ache around the AC joint.
At week nine, I stopped the oral BPC and switched to injectable BPC-157, using 250 mcg subq near the Achilles insertion once daily for six weeks. This was where the experiment changed for me. Over the next several weeks, my Achilles pain went from a daily 4/10 to more like 1–2/10. I started easing back into box jumps very cautiously, and by the end of that six-week run, I was doing them again for the first time in about a year and a half. That felt like a big deal.
The shoulder was less impressive. Around week ten, I added TB-500 at 2 mg per week IM for six weeks, mostly because the shoulder was still bothering me. It did improve somewhat, but not in the same obvious way as the Achilles. It could have been the TB-500, it could have been time, or it could have been that I was being more careful with training. Hard to say. I’d call it probably worth it, but I wouldn’t oversell it.
The vendor was a research-chem company. There wasn’t really a legitimate telehealth route for BPC available to me at the time, at least not one I could find. The full run cost around $320. Looking back, the biggest thing I regret is not testing the product. At the time, I trusted the vendor because other people were using them. About 18 months later, that same vendor had a public quality issue, and that made me wonder what I had actually been injecting. That part still bothers me.
If I were doing it again, I would probably skip the oral version and start with injectable, especially for the Achilles. The oral BPC may have helped a little, but compared with the injectable, it was underwhelming. I also think I gave PRP too much credit for too long. It did help for a while, so I don’t want to call it useless, but in hindsight, I wish I had tried BPC before spending more time and money in that direction.
The other thing I would change is the rehab side. I kept training, but I didn’t run a proper load progression. No formal eccentric loading plan, no structured return-to-jumping work, no real tracking beyond pain and what I could tolerate that day. That was dumb in hindsight. BPC was not a replacement for rehab. I do think it helped, especially the injectable near the Achilles, but the tendon still needed boring, consistent loading.
Overall, oral BPC-157 didn’t do much for me. Maybe a little, but nothing I’d call dramatic. Injectable BPC near the Achilles was a different story. After six weeks of that, I was doing box jumps again for the first time in about 18 months. The shoulder improved too, but not enough for me to pretend it was some miracle recovery.
I’d probably do it again, but I’d do it differently. I’d start with injectable, test the vendor first, and take the rehab plan much more seriously from day one.
What would have helped me most at the time was a real week-by-week walkthrough. Not just “here’s a BPC stack,” but something more practical: what to measure at week zero, what movements to stop, what loading to keep, what should be improving by week four, when to adjust by week eight, and how to return to jumping or heavier training without immediately flaring everything back up.
Most of the content I found made BPC sound like the whole story. For me, it wasn’t. The peptide may have opened the door, but the load progression was what actually got me through it.
Read full experience

Share your TB-500 experience →Browse all community experiences

Community Notes

0 approved · moderated

Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.

No approved notes yet.

Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.

Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.

← All peptides